Summarizing experience and further up-grading the heart and lung transplantation level in China

Chun-sheng WANG

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2010.08.001

2010-01-01

Abstract:1978年张世泽教授在上海完成了我国首例原位心脏移植术,此后经过14年的沉寂,自1992年起,我国心脏移植才逐渐开展,但未成规模,多为零星开展,投入很大,但围手术期并发症发生率及受者的死亡率偏高。

What problem does this paper attempt to address?

Liver Transplantation in Patients with Liver Failure: Twenty Years of Experience from China

Sunbin Ling,Guangjiang Jiang,Qingyang Que,Shengjun Xu,Junli Chen,Xiao Xu

DOI: https://doi.org/10.1111/liv.15288

IF: 8.754

2022-01-01

Liver International

Abstract:Liver transplantation (LT) is the only effective method of treating end-stage liver disease, such as various types of liver failure. China has the largest number of patients with hepatitis B virus-related disease, which is also the main cause of liver failure. From the first LT performed in 1977, and especially over the past two decades, LT has experienced rapid development as a result of continuous research and innovation in China. China performs the second-highest number of LTs every year worldwide, and the quality of LT continues to improve. Starting January 1, 2015, all donor's livers have been from deceased donors and familial donors. Thus, China entered into a new era of LT. However, LT is still a challenging procedure in China. In this review, we introduced the brief history of LT in China, the epidemiology, aetiology and clinical outcomes of LT for liver failure in China and summarized the experience of LT from Chinese LT surgeons and scholars. The future perspectives of LT were also discussed, and it is expected that China's LT research could be further integrated elsewhere in the world.
Extended criteria donor reconditioning and functional improvement in the viewshed of machine perfusion plus

汪恺,苏仁义,王周城,徐骁

DOI: https://doi.org/10.3760/cma.j.cn115610-20211220-00668

2022-01-01

Abstract:Liver transplantation (LT) is one of the most effective treatments for end-stage liver diseases. The number of LT in China currently ranks as the second worldwide. Extended criteria donor (ECD) reconditioning and functional improvement is an important research direction at present in order to address the bottleneck of donor graft shortage. In the future, it is pivotal to explore the original breakthroughs in basic theories of stem cell fates regulation, organ restoration and tissue regeneration, and to conduct national-wide, multicenter clinical investigations on the basis of innovative platform of medical, engineering and information technology. Therefore, the authors summarize evidence-based medical proof, latest research achievements and clinical experi-ences with novel concept of "machine perfusion plus" to explore the most updated mode that inte-grates traditional machine perfusion with cutting edge technologies such as multi-omics, molecular biology, information technology, automation technology and nanoparticle targeted delivery tech-nology. This aims to achieve real-time, non-invasive, intelligent quality assessment and monitoring of donor graft, and finally to establish a new technology system of ECD reconditioning and functional improvement, which can safely and effectively expand the donor pool, decrease the risk of post-transplant complications, and improve the prognosis of recipients, thus promoting the higher quality development of LT in China.
Current Status of and Opinions on Heart Transplantation in China

Yong-feng Sun,Zhi-wen Wang,Jing Zhang,Jie Cai,Feng Shi,Nian-guo Dong

DOI: https://doi.org/10.1007/s11596-021-2444-9

2021-10-01

Current Medical Science

Abstract:The purpose of this review is to provide a comprehensive update on recent advances in heart transplantation in China. Despite advances in pharmacologic and device treatment of chronic heart failure, long-term morbidity and mortality remain high, and many patients progress to endstage heart failure. Heart transplantation has become standard treatment for selected patients with end-stage heart failure, though challenges still exist. However, multiple advances over the past few years will improve the survival and quality-of-life of heart transplant recipients. This article elaborates on the specific characteristics of heart transplantation in China, the current issues, development trends, and related experiences with heart transplantation in Wuhan Union Hospital.

medicine, research & experimental
Recent Status of Heart Transplantation in Chinese Multi-Centers

HU Sheng-shou,WANG Chun-sheng,DONG Nian-guo,CHEN Liang-wan,MENG Xu

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2012.05.002

2012-01-01

Abstract:Objective To know the recent status of heart transplantation in Chinese multicenters.Methods The retrospectively data from 24 centers before 2010 (438 cases) and the data from China heart transplant Registry database between 2010 (149 cases from 15 centers)-2011(148 cases from 19 centers) were analyzed.Results In 2010,15 centers performed heart transplantation,including one large-scale center (60 transplants per year),3 moderate-scale centers (10 to 30 transplants per year),and 6 small-scale center (2-8 transplants per year).The rest 5 centers had one transplant per year each.In 2011,19 centers performed heart transplantation,including one large-scale center (52 transplants per year),3 moderate-scale centers (10 to 30 transplants per year),and 5 small-scale centers (2-8 transplants).The rest 8 centers had one transplant per year each.In 2010 and 2011,the median ages of heart transplant recipients were 44.6 and 42.9 years,respectively.Nonischemic cardiomyopathy was the leading indication for heart transplantation.The median donor age in 2010 and 2011was 30.2 and 30.8 years respectively.In 2010 and 2011,up to 99.3％ and 97.3％ of patients were treated with immune induction therapy,respectively.In 2010,the mortality at discharge was 10％,and that was 6％ in 2011.Conclusion Although total volume of heart transplants is still small in recent years,the discharge survival in China is similar to ISHLT report.
Current Situation of Heart Transplantation:Chinese Heart Transplant Annual Report 2013

Hu Shengshou,Dong Nianguo,Wei Xiang,Chen Liangwan,Wang Chunsheng

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2014.06.002

2014-01-01

Abstract:Objective To summarize and analyze the primary data from China Heart Transplant Registry in 2013 in order to explore the current status of heart transplantation in Chink Method Seventeen transplant centers have conducted 231 cases of heart transplantation in the year 2013.We analyzed the preoperative risk factors which impacted the survival of heart transplant recipients by using univariate and multivariate logistic regression analysis.And long-term survival of the 398 heart recipients from Beijing Fu Wai Hospital,who were followed up from June 2004 to December 2013 (follow-up rate was 100 ％) was calculated by the Kaplan-Meier method.The risk factors for long-term survival of heart transplant recipients were calculated by the COX survival analysis methods.Result The mean hospital stay of the 231 recipients was 24 days.There were 25 cases who died in hospital,and the total mortality was 10.8 ％ (25/231),while the average in-hospital mortality was 2.2 ％ in the three largest centers.By using the univariate and multivariate logistic regression analysis,we found that recipients" positive PRA was the only preoperative risk factor which impacted the in-hospital mortality.(OR=12.435,95％ CI 1.369～ 112.938,P =0.025).The median follow-up time of the 398 heart transplant recipients from Beijing Fu Wai Hospital was 1383 days,and the 1-,3-,5-and 7-year survival rate was 94.7％,91.6％,88.0％ and 82.6％ respectively.The univariate and multivariate COX regression analysis revealed that preoperative primary diseases (coronary heart disease vs.cardiomyopathy,P ＜ 0.01),the history of chronic obstructive pulmonary disease (P ＜ 0.01),the preoperative total bilirubin level (P＜0.05) and serum creatinine level (P＜ 0.01) were risk factors affecting long-term postoperative survival.Conclusion In China the number of heart transplants has increased in 2013.The survival rate of recipients is high in large heart transplant centers.The integrity of registration data needs to be further improved in some centers.
Orthotopic Heart Transplantations for End-Stage Heart Diseases

王春生,陈昊,洪涛,赵强,丁文军,宋凯,赖颢,赵东,杨守国,胡克俭

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2006.03.007

2006-01-01

Abstract:Objective To summarize the outcomes and clinical experience of orthotopic heart transplantations in Shanghai Zhongshan Hospital.Methods From May 2000 through October 2005,141 patients,101 males and 40 females,diagnosed as having dilated cardiomyopathy in 118,hypertrophic cardiomyopathy in 2,restrictive cardiomyopathy in 2,end-stage ischemic heart disease in 9, primary malignant cardiac tumor in 4,valvular heart disease in 3 and others in 3,underwent orthotopic heart(transplantations) at our center.The operative procedures included 120 bicaval anastomotic cardiac transplantations,19 conventional Stanford orthotopic cardiac transplantations and 2 total heart transplantations.The immunosuppressive therapy strategies included Cyclosporine A or tacrolimus,corticosteroids and mycophenolate mofetil.For the latest 28 patients,induction therapy with Daclizumab was applied.Results There were 3 operative deaths with an operative survival of 97.9 %.During the follow-up from 1 month to 65 months,the actuarial survival rate was 90.8 % after 1 year,84.6 % after 3 year and 81.4 % after 5 year.Acute rejection,infections,graft failure and metastasis of primary cardiac tumor were the main causes of death in the 1st postoperative year,while acute rejection and graft coronary vasculopathy were the leading causes of death thereafter.Postoperative complications included acute rejection,infections,renal dysfunction and graft failure.Conclusions Orthotopic heart transplantation was proved to be a reliable choice for endstage heart disease with excellent outcomes.More attention should be paid to surveillance and management of acute rejection, infections and graft coronary vasculopathy in the long-term follow-up.
Twenty-nine Years Experience of Kidney Transplantation from Zhejiang University.

Jianghua Chen,Lihui Qu,Jianyong Wu,Yiming Wang,Jianguo Zhang,Zhangfei Shou,Huiping Wang,Hongfeng Huang,Qiang He,Ping Zhang,Xiaohui Zhang,Zong Zhu

2005-01-01

Abstract:During the last 29 years the dramatic changes that have taken place in our transplant programs and in solid organ transplantation permit us to face tomorrow with courage and confidence. In the future we will be deeply concerned that the long-term benefit of more effective immunosuppression or novel strategies might be unfavorably impacted by the tendency to use organs whose intrinsic lifespan may be limited. We are deeply concerned by the inexorably increasing discrepancy between supply and demand for deceased kidneys, especially for the added morbidity that this inevitably entails for those patients with ESRD who do not have live donors. Our program continues to seek better ways to improve survival and the quality of the life of our patient population.
China Lung Transplantation Developing: Past, Present And Future

Bo Wu,Chunxiao Hu,Wenhui Chen,Jianxing He,Gening Jiang,Ji Zhang,Dong Liu,Xiaoshan Li,Dong Wei,Guohui Jiao,Chen Wang,Jingyu Chen

DOI: https://doi.org/10.21037/atm.2019.10.26

IF: 3.616

2020-01-01

Annals of Translational Medicine

Abstract:Lung transplantation in China has been developing for almost 40 years (1979-2019). The pioneers of this procedure experienced struggles and obstacles upon accomplishment of the initial 20 cases of lung transplantation. Like the expanding process of transplant programs elsewhere in western countries and other regions in Asia, transplant teams in China have found their own way to step forward, with the establishment of the two largest centers in Beijing and Wuxi. Since 2015, which was a novel start and milestone for transplant affairs in China, the pace of transplant volume and comparable quality of care for lung transplant recipients have increased noticeably. We reviewed the advancement of lung transplantation programs and registry setup in China and indicated that more socioeconomic factors and human care aspects needed to be considered to benefit Chinese recipients, which may further inspire the modification of criteria of listing and organ utilization based on East Asian cultural and traditional origins.
[Orthotopic Heart Transplantation: Clinical Experience on 56 Patients].

Chun-sheng Wang,Hao Chen,Tao Hong,Qiang Zhao,Wen-jun Ding,Yi-qing Wang,Kai Song,Hao Lai,Dong Zhao,Shou-guo Yang

DOI: https://doi.org/10.3760/j:issn:0376-2491.2004.19.003

2004-01-01

Abstract:OBJECTIVE:To summarize the clinical experience on 56 patients undergoing orthotopic heart transplantation.METHODS:Between May 2000 and December 2003 56 patients, 47 with cardiomyopathy, 2 with end-stage valvular heart disease, 2 with end-stage ischemic heart disease, 2 with primary malignant cardiac tumor, 1 with complicated congenital heart disease, 1 with muscular dystrophy cardiomyopathy, and 1 with refractory malignant ventricular arrhythmias, underwent orthotopic heart transplantation in the Transplantation Center of Fudan University. The operative procedures included 19 conventional Stanford orthotopic cardiac transplantation in 19 cases and bicaval anastomotic cardiac transplantation in 37 cases. Postoperatively, the patients were prescribed with cyclosporine A + corticosteroids + MMF or FK506 + corticosteroids + MMF as anti-rejection therapy.RESULTS:One patient undergoing his fifth operation died of bleeding 3 days after operation. All survivors were followed-up for 12.4 months on average. Five patients died within 1 year postoperatively with a one-year survival rate of 91%. One patient died of allograft vasculopathy 38 months after operation. Other patients enjoyed heart function recovering to class I-II (NYHA).CONCLUSION:With proper recipient selection, excellent donor heart conservation, bicaval anastomotic technique, and efficient postoperative surveillance and treatment, heart transplantion may produce satisfying mid-term results.
Initial Experience of Lung Transplantation at A Single Center in China

W. Mao,J. Chen,M. Zheng,B. Wu,Y. Zhu

DOI: https://doi.org/10.1016/j.transproceed.2012.02.045

IF: 1.014

2013-01-01

Transplantation Proceedings

Abstract:Objectives. Lung transplantation (LT) remains the only available option for patients with end-stage lung disease. Until recently, 244 lung transplantations have been performed at approximate 20 institutes in China. The aim of this article was to present the initial experience of LT at a single center in China.Methods. We performed a retrospective review of the database from The Chinese Organ Transplantation Network between January 1978 and December 2010 with detailed records available at our center.Results. We performed 100 of 244 lung transplantions at the Wuxi Center, The remaining procedures were performed at other institutes. The overall survival rates for these patients at 1, 2, 3, and 5 years were 73.3%, 61.6%, 53.5%, and 40.7%, respectively. The indications for lung transplantation included idiopathic pulmonary fibrosis (n = 47), chronic obstructive pulmonary disease (n = 33), silicosis (n = 5), bronchiectasis (n = 5), and Eisenmenger's syndrome (n = 4). The procedure types consisted of single-lung transplantations (s; n = 72), and bilateral lung transplantations (s; n = 28). Cardiopulmonary bypass was required in 5 patients, whereas 56 required arteriovenous extracorporeal membrane oxygenation, including extended use in 3 before and 10 after LT. The main morbidities and complications after LT were sepsis (n = 11), primary graft dysfunction (PGD, n = 10), anastomotic stenosis (n = 10), acute rejection episodes (n = 25), and bronchiolitis obliterans syndrome (n = 15). In-hospital mortality was 18%, including sepsis (n = 10), POD (n = 6), acute rejection episode (n = 1) and pulmonary infarction (n = 1). The mean survival time was 3.4 years.Conclusions. In China, lung transplantation may offer a viable therapy for patients with various end-stage pulmonary conditions. The initiation of LT should focus on improving the survival rate by increased clinical practice.
Life First and Science Respect:A Commentary on Current Status and Expectations of China's Lung Transplantation

WU Bo,HU Chunxiao,LI Xiaoshan,CHEN Jingyu

DOI: https://doi.org/10.14188/j.1671-8852.2021.6001

2021-01-01

Abstract:Lung transplantation is the only effective method for the treatment of end-stage lung diseases. Lung transplantation has achieved rapid development in the world. At present, about 4 000 cases are carried out every year, and the long-term survival rate has gradually improved. With a high incidence of lung disease in China, at least ten thousand patients with respiratory failure need lung transplantation every year. In 2020, 29 lung transplantation centers in China has carried out more than 500 cases of lung transplantation. Idiopathic pulmonary interstitial fibrosis, chronic obstructive pulmonary disease, secondary pulmonary interstitial fibrosis and pneumoconiosis were the main primary diseases in lung transplantation recipients in China. Single-lung transplantation accounted for 57.6% and double-lung transplantation accounted for 42.4%, respectively. Peri-operation (<30 days), one-year, and three-year survival rates were 78.5%, 64.5% and 48.9%, respectively for double-lung transplant. The corresponding survival rates for single-lung transplant recipients were 83.0%, 69.9% and 46.8%, respectively. The Renmin Hospital of Wuhan University completed the first case of COVID-19 lung transplantation operation in Hubei Province in 2020, and the patients recovered and discharged successfully after the operation. Although China has made great progress in lung transplantation, it is still necessary to realize that the multi-disciplinary team cooperation mode and data registration management still need to be further strengthened, in order to provide more clinical guidelines and expert consensus and make the steady development and improvement of each lung transplantation center. The lung transplantation in China will be gradually promoted to the center of the organ transplantation stage in the world. © 2021, Editorial Board of Medical Journal of Wuhan University. All right reserved.
Long-term results of 298 cases of orthotopic heart transplantations: a single center experience

YANG Shou-guo,WANG Chun-sheng,CHEN Hao,HONG Tao,HU Ke-jian,ZHUANG Ya-min,LIN Yi,YANG Zhao-hua

DOI: https://doi.org/10.3877/cma.j.issn.1674-3903.2011.02.003

2011-01-01

Abstract:Objective To summarize the 11 years' heart transplantation results at single center and analyze the risk factors of long term survival.Methods From May 2000 to April 2011, 298 patients, including 235 males and 63 females, underwent orthotopic heart transplantation in Zhongshan Hospital of Fudan University. Etiology comprised 73.2% dilated cardiomyopathy, 8.7% ischemic heart disease, 6.4% valvular heart disease, 2.6% primary malignant cardiac tumor, and 0.7% cardiac allograft arteriosclerosis. Donor heart grafts were harvested with beating hearts in 238 cases and with fibrillated hearts in 60 cases. Heart grafts were preserved with St. Thomas solution and UW solution, with cold ischemic time ranging from 69 to 600 min, (191.0±28.5)min on average. The operative procedures included 272 bicaval anastomotic cardiac transplantations, 19 conventional Stanford orthotopic cardiac transplantations, and 7 total heart transplantations. Postoperatively, immunosuppressive therapy strategies included cyclosporine or tacrolimus, corticosteroids, and mycophenolate mofetil. Induction therapy with daclizumab was applied in the latest 85% patients. Regular follow-up was arranged postoperatively.Results All recipients were followed up with duration from 1 to 121 months, (42.5±9.8) months on average. The actuarial survival rate was 90.8% after 1 year, 82.8% after 3 year, 73.4% after 5 year, and 65.2% after 8 year. Graft failure, acute rejection, infections, metastasis of primary cardiac tumor, and sudden death contributed to the main causes of death in the 1st postoperative year, while graft coronary vasculopathy, graft failure, acute rejection, infections, and renal failure contributed to most of long-term mortality. Ninety percent of survivors (243 cases) enjoyed heart function of class Ⅰ-Ⅱ (NYHA) and 20% of them resumed full-time job.Conclusion Long-term results of heart transplantation in the 298 patients proved to be promising and stable. Regular follow-up with more attention on surveillance and management of acute rejection, graft coronary vasculopathy and infections should result in a better long-term survival.
Preliminary Experience of 11 Successful Orthotopic Heart Transplantations

王春生,洪涛,赵强,陈志强,陈昊,宋凯,丁文军,赖颢,姜桢,金翔华,舒先红,王齐冰,葛均波

DOI: https://doi.org/10.3760/j:issn:0253-3758.2002.01.010

2002-01-01

Abstract:Objective To report our early experience on 11 successful heart transplantations Methods Between May 2000 and May 2001, 11 patients, aged from 12 to 52 years, with diagnosis of dilated cardiomyopathy in 10 and complicated congenital heart disease in 1, underwent orthotopic heart transplantation at our institute The operative procedures included 10 conventional Stanford orthotopic cardiac transplantation and 1 bicaval anastomotic cardiac transplantation Postoperatively, 6 cases were prescribed with Cyclosporine A+ Corticosteroids+MMF, the others with FK506+Corticosteroids+MMF Results All patients survived In the perioperation period there were no infection or rejection During follow up period, all patients resumed daily work and their cardiac function recovered to grade I II(NYHA);only one patient suffered from cytomegalovirus infection and one acute rejection Conclusion Excellent donor heart conservation and proper immunosuppression treatment were key measures of successful heart transplantation
Three Year’s Experience of Lung Transplantation for End-stage Pulmonary Disease.

Chen Jingyu,Zheng Mingfeng,Hu Chunxiao,Zhu Yanhong,He Yijun,Wang Yonggong,Zhou Min,Lu Minghua

DOI: https://doi.org/10.3969/j.issn.1673-548X.2007.02.023

2007-01-01

Abstract:Objective To discuss the feasibility of the lung transplantation as an effective treatment for end-stage pulmonary disease domestically. To compare the major issues involving the practice of lung transplantation domestically and overseas.Methods After the foundation of group of lung transplantation in May 2002, we have set up lung transplantation models of porcine. From September. 2002 to August 2005, the 24 LT that were performed included 20 single-lung transplants SLT (83.3%) and 4 Bilateral sequential single lung transplants (BSSLT) (16.7%),among them only one case receive BSSLTx with CPB. Indications for SLT (n=20) , emphysema (n=9),pulmonary fibrosis (n=8),pneumosilicosis(n=1),lymphangioleiomyomatosis(n=1) and ventricular septal defect(VSD) induced Eisenmenger’s syndrome(n=1); for BSSLT (n=4) were bronchiectasis (n=2) and pulmonary emphysema(n=2). 20 SLTs include 11 left single lung transplantation and 9 right lung transplantation. Among them, 2 cases share one same donor’s lung block, one case of contralateral lung transplantation-a left donor lung implanted in the recipient’s right thorax, one cases of simultaneous right single lung transplantation and ventricular septal defect repair. One case receive right single lung transplantation with CPB. Results In-hospital mortality (HM) was 5/24 (20.2%). Among SLT, early death was due to severe infection on the 30th postoperative day in two patient and acute rejection on the 15th postoperative day in other patients ,and another patient died due to pulmonary vein embolism on the 36th day. The patient who is received BSSLTx with CPB died because of acute heart failure. And The patients survived longer than1,2,3 years were 1,2,1 cases respectively. The median overall survival was 10 (1 to 36) months. Conclusions Our LT program shows similar results to those reported by the International Society for Heart and Lung Transplantation for developed countries. A rapid development era of lung transplantation is emerging in China. The key of successful operation depends on the establishment of group of lung transplantation and cooperation of multi-department. Ischemic-reperfusion injury, acute-rejection and infection are the major reasons of deaths shortly after the operations.
[Promoting Improvement of Liver Transplantation in China].

Shu-Sen Zheng,Ting-Bo Liang

DOI: https://doi.org/10.3760/j.issn:1007-3418.2004.06.001

2004-01-01

Abstract:Liver transplantation is the only cure for end stage liver diseases. Although liver transplantation started lately in China, it has evolved rapidly during the last decade. The graft and patient survival have increased significantly, and the long-term curative effect has been promisingly improved. In some large transplantation centers in China, liver transplantation has been a routine operation. However, liver transplantation in China has not yet formed its own characteristics, and its basic research, cross-discipline development, long-term survival rate, and post-operational management still drop behind the international advanced levels. It is important to summarize our experience, standardize its rule, and innovate its technique, so as to improve the outcomes of liver transplantation in China in the future. This article briefly overviews the status quo, existing problems, and further development of liver transplantation in China.
Clinical Experience in Liver Transplantation from an Organ Transplantation Center in China.

Shu-Sen Zheng,Ting-Bo Liang,Wei-Lin Wang,Dong-Sheng Huang,Yan Shen,Min Zhang,Xiao Xu,Ling-Jun Mou

2002-01-01

Abstract:OBJECTIVE:To sum up the experience in liver transplantation in a period of ten years at a single center.METHODS:We retrospectively reviewed the clinical records of 120 patients receiving liver transplantation from April 1993 to October 2002. The patients' clinical characteristics, surgical techniques, complications and survival were compared in the phases of 1993-1997 (phase I), 1999 (phase II), and 2000-2002 (phase III).RESULTS:Malignant liver diseases were major indications for liver transplantation in phase I (100%) and II (53.3%), but decreased markedly in percentage in phase III (34.0%). When compared with recipients in phase I and II, the survival of recipients with benign liver diseases in phase III was significantly improved with the 3-month, 6-month and 1-year survival rates of 85.7%, 84.5% and 83.1%, respectively. For patients with malignant liver diseases, the 3-month, 6-month and 1-year survival rates were 87.4%, 81.1% and 46.0%, respectively. The reinfection rate of hepatitis B virus was 24% 12 months after transplantation. With technical refinements, the incidence of postransplantation vascular complications has significantly decreased from 29.4% in phase I and II to 4.9% in phase III. Biliary complications remained one of the major obstacles to long-term survival. No veno-venous bypass was applied in phase III, providing a promising outcome.CONCLUSION:Strict selection of potential recipients, technical refinement, appropriate management of vascular and biliary complications, and prophylaxis of recurrences of hepatitis B and malignant liver diseases are important to obtain long-term survival of patients receiving liver transplantation in China.
Initial Experience of Lung Transplantation Using Voluntary Organ Donations after Brain and Cardiac Death of Citizens at Wuxi Center: Tough Sail in 2015

W. Mao,J. Chen

DOI: https://doi.org/10.1097/01.tp.0000520372.61075.6a

2017-01-01

Transplantation

Abstract:Introduction: The purpose of the study was to estimate the initial experience in lung transplantation using lungs from donation after brain and cardiac death (DBCD) or donation after brain death (DBD) in china. Methods: Retrospective data from Chinese network registry for lung transplantation performed in our center were evaluated between January and December, 2015. Characteristics of donors and recipients were reviewed. Results: A total of 103 cases donated their lungs, including 69 DBDs and 34 DBCDs, the main causes of death were 49 (48%) cases of craniocerebral trauma and 54 (52%)cases of celebral vascular incidence. The mean age for these donors were 33.41 (15–57) years old, with a mean ventilation time of 3.77 (1–15) days in the intensive care unit. Two days were frequently required for us to perform organ procurement, and it was hard to transport the donor lungs to our center in China, such as 1–4 hours by highway, 4–6 by highway and high-speed rail, 5.5-9.5 hours are needed by civil aviation, high-speed rail, and highway. There were 107 lung transplantation performed using lungs from DBCD or DBD for 106 patients during the study period. The mean age of recipients was 53.68 (13–73) years old. Eighty patients were males and 27 were females, 75 patients received bilateral lung transplantation, 23 underwent right single lung transplantation, and the remaining 9 received left single lung transplantation, including 2 cases of bilateral split lobar transplantations, 3 secondary lung transplantations for bronchiolitis obliterans, and 1 secondary lung transplantation for severe primary graft dysfunction. The main indications of the cohort includes 53 cases of idiopathic pulmonary fibrosis, 17 chronic obstructive pulmonary disease, 13 silicosis, 11 bronchiectasis, 5 lymphangioleiomyomatosis, 3 bronchiolitis obliterans, and 2 graft versus host lung disease after allogenic hematopoietic stem cell transplantation, 1 eisenmenger syndrome, and 1 chronic pulmonary embolism. Extracorporeal membrane oxygenation(ECMO) was utilized in 44.3% of the patients (47 cases), with 36 recipients weaned from ECMO immediately after transplants. There were 15 death during perioperative period, early survival of 3-month and 6-month were 85.84% and 83.19%, respectively. Conclusion: This small restrospective study shows that current lung transplant program may expand donors after DBCD and DBD in China with considerable difficulties.
Liver Transplantation in China: Problems and Their Solutions.

Jian Wu,Shu-Sen Zheng

2004-01-01

Abstract:BACKGROUND:The past decade has witnessed the rapid development of liver transplantation in China. The 1-year survival of liver transplant patients comes to 80% in many leading medical centers and the number of liver transplantation is increasing. However, liver transplantation in China is facing several challenges including recipient with hepatocellular carcinoma (HCC), recurrence of HCC and hepatitis B, long-term postoperative care, the bridge to liver transplantation, and shortage of liver donor. This review was to understand the status of and problems in liver transplantation in China.DATA RESOURCES:An English-language literature search using MEDLINE (1990-2003) on liver transplantation and other related reports and review articles in Chinese from major transplant centers in China.RESULTS:HCC is one of the main indications for liver transplantation in China but different centers adopted different criteria for selection of patients. Hepatitis B virus reinfection is a vital problem after liver transplantation in HBV-related patients. More and more attention was focused on long-term postoperative care and donor shortage. Artificial liver support system has been applied in patients waiting for a graft in many centers.CONCLUSIONS:HCC remains to be one of the main indications for liver transplantation in China; combined hepatitis B immune globulin and lamivudine is considered effective to prevent hepatitis B virus reinfection. Apart from long-term postoperative care for the improvement of the survival rate, early steroid withdrawal is feasible in liver transplantation. Living donor liver transplantation, split liver transplantation, and marginal donor transplantation can deal with donor shortage to some extent. Artificial liver assist system serves as a bridge to liver transplantation.
Lung Transplantation In China Between 2015 And 2018

Chun-Xiao Hu,Wen-Hui Chen,Jian-Xing He,Ge-Ning Jiang,Xiao-Shan Li,Dong Wei,Bo Wu,Ji Zhang,Chen Wang,Jing-Yu Chen

DOI: https://doi.org/10.1097/CM9.0000000000000543

IF: 6.133

2019-01-01

Chinese Medical Journal

Abstract:Background:Lung transplantation (LT) has been demonstrated as the only effective therapy for patients with end-stage lung diseases. Increasing listed lung transplant candidates and expanding volumes of lung transplant centers across China require well-organized programs and registry data collection based on the large population. This study aimed to summarize and analyze the data of LT development in China.Methods:We retrospectively collected and analyzed data from the China Lung Transplantation Registry (CLuTR). Key data were reported from the registry with transplant types, indications, donor and recipient characteristics, outcomes and survival. The survival <30 days, 1-year and 3-year survival rates were estimated with risk factors identified.Results:CLuTR contained data from 1053 lung transplants performed through January 1st, 2015 to December 31st, 2018 reported by 18 registered transplant centers. The largest category of diagnosis before transplantation was idiopathic interstitial pneumonitis. The total 30 days, 1-year and 3-year survival rates in CLuTR were 81.45%, 70.11%, and 61.16% with discrepancy by indications. Large proportion of recipients who were more than 60 years old required higher standard of care. Infection-related complications resulted in more death events in the early post-surgery periods. New York Heart Association grading at listing, extra-corporeal membrane oxygenation usage peri-transplantation, allograft dysfunction (primary graft dysfunction >Grade 0), renal insufficiency (estimated glomerular filtration rate <60 mLmin(-1)1.73 m(-2)), were independently associated with a higher risk for 3-year mortality in the entire cohort.Conclusions:Facing more end-stage of lung diseases and comorbidities, this study analyzed the outcomes and survival of LT recipients in China. Further prospectively stratified analyses with longer follow-up will be needed.
Difficulties and Countermeasures of Lung Transplantation in China

Mao Wenj un,Chen Jingyu

DOI: https://doi.org/10.3877/cma.j.issn.2095-8773.2016.01.001

2016-01-01

Abstract:Lung transplantation is the only effective method to treat some lung diseaseswhich can greatly improve the quality of life after operation and significantly prolong the survival.Howevercompared with liver and kidney transplantationthe numbers of lung transplantation are smaller in most transplant centersand the operation technique is less maturewhich largely restricted the development of lung transplantation.By years of effortsthe clinical practice of lung transplantation has experienced dramatic development in China but countermeasures are required to deal with current enormous problems.

Summarizing experience and further up-grading the heart and lung transplantation level in China

Liver Transplantation in Patients with Liver Failure: Twenty Years of Experience from China

Extended criteria donor reconditioning and functional improvement in the viewshed of machine perfusion plus

Current Status of and Opinions on Heart Transplantation in China

Recent Status of Heart Transplantation in Chinese Multi-Centers

Current Situation of Heart Transplantation:Chinese Heart Transplant Annual Report 2013

Orthotopic Heart Transplantations for End-Stage Heart Diseases

Twenty-nine Years Experience of Kidney Transplantation from Zhejiang University.

China Lung Transplantation Developing: Past, Present And Future

[Orthotopic Heart Transplantation: Clinical Experience on 56 Patients].

Initial Experience of Lung Transplantation at A Single Center in China

Life First and Science Respect:A Commentary on Current Status and Expectations of China's Lung Transplantation

Long-term results of 298 cases of orthotopic heart transplantations: a single center experience

Preliminary Experience of 11 Successful Orthotopic Heart Transplantations

Three Year’s Experience of Lung Transplantation for End-stage Pulmonary Disease.

[Promoting Improvement of Liver Transplantation in China].

Clinical Experience in Liver Transplantation from an Organ Transplantation Center in China.

Initial Experience of Lung Transplantation Using Voluntary Organ Donations after Brain and Cardiac Death of Citizens at Wuxi Center: Tough Sail in 2015

Liver Transplantation in China: Problems and Their Solutions.

Lung Transplantation In China Between 2015 And 2018

Difficulties and Countermeasures of Lung Transplantation in China